Navigation Links
New Study Shows Impressive Results with Abutment-Free Sophono System
Date:2/7/2013

Boulder, Colo. (PRWEB) February 07, 2013

Children with the abutment-free, implantable bone conduction hearing device from Sophono, Inc., experienced significant improvement in hearing – without skin complications – according to a new study.

Sophono, Inc., is a Colorado-based medical device manufacturer. The Sophono Alpha System™ is the only abutment-free, implantable, bone-anchored hearing system on the market, treating those with conductive hearing loss, mixed hearing loss and single-sided deafness. Fitted to the patient’s head with the use of small, implantable magnets, the Sophono Alpha System eliminates the problems associated with other bone conduction hearing systems. These include drilling a hole in the patient’s skull and installing a very noticeable screw that pokes out through the skin on the side of the head.

The article summarizing the study findings, with preliminary results on how Sophono’s closed-skin bone-anchored implant worked in children with ear atresia, appears in the February issue of Otology & Neurotology. The study, conducted in Hôpital d’Enfants Armand-Trousseau (Paris Childrens’ Hospital) in 2012, evaluated the results of children between 6 and 9 years old. All had high-grade ear atresia, defined as the absence an external ear canal and resulting in the child’s inability to hear in the affected ear. A review of patient benefit at six months of use with the Sophono system showed that the children experienced the following.

1.    Hearing levels improved from severe conductive loss to nearly normal hearing.

2.    A high level of overall satisfaction – among both children and their parents


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Page: 1 2

Related biology technology :

1. EU Study Finds UK Health Product Benefit Metric Flawed
2. Notre Dame study explores the potential benefits and threats of nanotechnology research
3. CSL Behring enrolls first patient in global pediatric Phase III pivotal study of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) to treat hemophilia B
4. University of Colorado Cancer Center Study Finds That Body's Ibuprofen, SPARC, Reduces Inflammation and Thus Bladder Cancer Development and Metastasis
5. Wysebridge Launches Patent Bar Exam Study Review
6. RPCI-Led Study: FAK Inhibitor Proves Effective Against Brain Tumors in Preclinical Studies
7. Spartan Bioscience Announces 6,000-Patient Study of Personalized Medicine for Cardiac Stents
8. Major Diabetes Peer-Review Journal Publishes Postive Results Of Ultradian Diagnostics Human Pilot Study
9. American Journal of Infection Control Study Validates ATP Testing for Monitoring Sanitation in Hospitals; Charm Sciences Test Verified
10. Study identifies targeted molecular therapy for untreatable NF1 tumors
11. Study Finds Proof of Acupuncture Success
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 29, 2015 GeneWEAVE, Inc ... (MDROs), announced that initial feasibility data supporting the ... and susceptibility testing from positive blood cultures will ... 31, 2015 in New Orleans, LA. The Company’s ... diagnostics that can quickly detect bacteria and assess ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Market ... (Chem-Report ) signed a partnership agreement for quality ... authorised to distribute and sell research reports worked ... at Partners Department, commented upon the agreement: “Chem-Report ... on key petroleum and chemical markets on global ...
(Date:5/29/2015)... 2015  Caris Life Sciences® today announced the ... researchers utilized Caris Molecular Intelligence®, the company,s panomic, ... targets in patients with colorectal and pancreatic cancer ... death protein 1 (PD-1) and its ligand, PD-L1. ... 2015 American Society of Clinical Oncology Annual Meeting ...
(Date:5/29/2015)... Md. and RESEARCH TRIANGLE PARK, N.C. ... (NASDAQ: UTHR ) announced today that Roger Jeffs ... will provide an overview and update on the company,s business ... New York City . The presentation and ... June 4, 2015, at 11:00 AM Eastern Time, and can ...
Breaking Biology Technology:Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 2Data Highlighting GeneWEAVE’s Smarticles™ Technology to be Presented at the 115th General Meeting of the American Society for Microbiology (asm2015) 3Market Publishers Ltd and Chem-Report Sign Partnership Agreement 2Market Publishers Ltd and Chem-Report Sign Partnership Agreement 3Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 2Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 3Multi-Platform Molecular Profiling from Caris Life Sciences Identifies Clinically Actionable Targets for Novel Immunotherapy Drugs 4
... Raymond and Ruth Perelman School of Medicine at ... of a first-of-its-kind interdisciplinary center focused on discovering ... bring together, without institutional walls, all necessary approaches ... research support facilities, translating findings into therapies, fostering ...
...   Elsevier, the leading provider of scientific, ... to outstanding members of the wilderness medicine community at this ... Conference & Annual Meeting , taking place in Snowmass, CO, ... The aim of the Wilderness Medicine Society is to ...
... 2011 Selexis SA , a global life science ... scale-up to manufacturing of therapeutic proteins announced today that CSL ... Selexis for the preclinical development of a therapeutic antibody ... in 2012. This commercial license agreement provides CSL with the ...
Cached Biology Technology:Penn Receives $10 Million to Create Center for Orphan Disease Research and Therapy 2Elsevier Collaborates with the Wilderness Medicine Society to Award Outstanding Members 2Elsevier Collaborates with the Wilderness Medicine Society to Award Outstanding Members 3CSL Limited Signs Commercial License Agreement with Selexis SA 2
(Date:5/11/2015)... JOSE, Calif. , May 11, 2015 /PRNewswire/ ... developer of human interface solutions, today announced the ... Vice President and Chief Financial Officer, reporting to ... Ali replaces Synaptics, current Chief Financial Officer, ... December 2014. Mr. Ali brings ...
(Date:5/11/2015)... RYE, N.Y. , May 11, 2015 ... company, announced the start of a new Phase III ... effect of its novel formulation, CM-AT, on all children ... results of its FDA Phase III double blinded clinical ... who had low levels of the digestive enzyme chymotrypsin. ...
(Date:5/8/2015)... , May 8, 2015 Synaptics Inc. (NASDAQ: ... announced that members of the executive management team will present ... Annual Technology, Media and Telecom Conference Date: May 18, ... Boston, MA Cowen and ... Time: 2:45pm ET Location: The New York Palace Hotel, ...
Breaking Biology News(10 mins):Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2Synaptics to Present at Upcoming Investor Conferences 2
... The National Science Foundation (NSF) is funding a new ... high-achieving science and math undergraduates for teaching careers. ... within the College of Arts and Sciences at Case ... majors to become high school math and science teachers. ...
... Assistant Professor of Biomedical Engineering and Orthopedic Surgery has ... in Aging by The Ellison Medical Foundation. Case Western ... to submit a proposal, and Alsberg was one of ... National competition was strong, with only 25 awards being ...
... virulent avian influenza virus strain called H5N1 forms tiny tubules ... during viral infection, which otherwise would prompt an antiviral immune ... in an online report in the journal Nature . ... to form tiny tubules where double-stranded RNA is hidden from ...
Cached Biology News:NSF grant to launch undergrads from Case Western Reserve into math and science teaching 2NSF grant to launch undergrads from Case Western Reserve into math and science teaching 3Case Western Reserve receives Ellison Medical Foundation New Scholar in Aging award 2Protein 'tubules' free avian flu virus from immune recognition 2
...
... RNase Inhibitor (Ribonuclease inhibitor) is ... used to inhibit RNase activity. ... or endonuclease activity. , ... of RNA template , ...
...
... GC-rich nucleic acids ,The GC-RICH PCR ... and a proofreading polymerase, powers through templates ... with other polymerases and other blends of ... and the unique GC-RICH Resolution Solution combine ...
Biology Products: